Overview
Connective tissue sarcomas are malignant tumors arising from mesenchymal cells, affecting various dense connective tissues such as tendons, ligaments, and skeletal muscles. These tumors are characterized by their aggressive behavior and potential for local invasion and metastasis 16.Diagnosis
Imaging studies (MRI, CT) for tumor extent and local invasion 1.
Biopsy with histopathological examination to confirm diagnosis 16.
Molecular markers and genetic testing may aid in classification and prognosis 4.
Desmosine and isodesmosine levels in biological fluids can indicate elastin degradation, relevant in certain subtypes 5.Management
First-line treatments: Surgical resection with clear margins is often the primary approach 16.
Adjuvant therapies: Radiation therapy for high-risk cases or incomplete resection 1.
Systemic therapy: For metastatic disease, consider chemotherapy regimens such as doxorubicin-based protocols 6.
Immunotherapy: Intravenous immunoglobulins (IVIGs) may be considered for therapy-resistant cases, though evidence is limited and requires further study 2.
Vitamin D: Currently insufficient evidence supports its routine use beyond monitoring deficiency 3.Special Populations
Pregnancy: Specific management guidelines are not detailed in the provided abstracts; individualized care based on risk assessment is recommended 6.
Pediatrics: Limited data; surgical intervention with multidisciplinary care is likely essential 1.
Elderly: Consider comorbidities and functional status; tailored treatment plans balancing efficacy and toxicity are crucial 6.
Comorbidities: Management should integrate care for concurrent connective tissue disorders, potentially leveraging insights from dermatological and rheumatological perspectives 26.Key Recommendations
Surgical resection with negative margins is recommended for localized sarcomas (Evidence: Strong 16).
Adjuvant radiation therapy should be considered for high-risk surgical margins or incomplete resection (Evidence: Moderate 1).
Intravenous immunoglobulins may be used cautiously in therapy-resistant cases, though more evidence is needed (Evidence: Weak 2).
Monitor and correct vitamin D deficiency, but do not routinely use vitamin D as a primary treatment adjunct (Evidence: Expert opinion 3).
Integrate multidisciplinary care, especially in special populations like the elderly and pediatric patients (Evidence: Expert opinion 6).References
1 Feng Y, Su L, Liu L, Chen Z, Ji Y, Hu Y et al.. Accurate Spatio-Temporal Delivery of Nitric Oxide Facilitates the Programmable Repair of Avascular Dense Connective Tissues Injury. Advanced healthcare materials 2024. link
2 Dourmishev LA, Guleva DV, Miteva LG. Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology. Wiener medizinische Wochenschrift (1946) 2018. link
3 Reynolds JA, Bruce IN. Vitamin D treatment for connective tissue diseases: hope beyond the hype?. Rheumatology (Oxford, England) 2017. link
4 Salnikova LE, Khadzhieva MB, Kolobkov DS. Biological findings from the PheWAS catalog: focus on connective tissue-related disorders (pelvic floor dysfunction, abdominal hernia, varicose veins and hemorrhoids). Human genetics 2016. link
5 Viglio S, Annovazzi L, Luisetti M, Stolk J, Casado B, Iadarola P. Progress in the methodological strategies for the detection in real samples of desmosine and isodesmosine, two biological markers of elastin degradation. Journal of separation science 2007. link
6 Mallia C. The interface between rheumatology and dermatology. Why rheumaderm?. Advances in experimental medicine and biology 1999. link
7 Kozminsky ME, Bronson DM, Barsky S. Zosteriform connective-tissue nevus. Cutis 1985. link
8 Scott JE. Proteoglycan histochemistry--a valuable tool for connective tissue biochemists. Collagen and related research 1985. link80008-x)
9 Judd KP. Hyperelasticity syndromes. Cutis 1984. link